Neoadjuvant chemotherapy: A standard treatment for locally advanced gastric cancer in the near future?

Gastric Cancer

Volumn 6, Issue 3, 2003, Pages 131-133

  Sakamoto, Junichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL; UFT;

CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; LAPAROSCOPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY; SIDE EFFECT; STANDARD; STOMACH CANCER; ULTRASOUND;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0141644271     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0254-3     Document Type: Editorial

References (11)

1. Ott K, Sendler A, Becker K, Dittler H-J, Helmberger H, Busch R, et al. Neoajuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159-67.
2. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229: 303-8.
3. Swisher SG, Holmes EC, Hunt KK, Doty JE, Zinner MJ, McFadden DW. The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg 1996;131:819-24.
4. Ajani JA, Mansfield PF, Lynch PA, Pisters PW, Feig B, Dumas P, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17(8):2403-11.
5. Bland KI. Utilization of sentinel lymph node mapping to determine pathologic outcomes for patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2002;9(3):217-9.
6. Chen CN, Cheng YM, Lin MT, Hsieh FJ, Lee PH, Chang KJ. Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg 2002;235(4):512-8.
7. Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003;9(6):2307-15.
8. Cascinu S, Graziano F, Barni S, Labianca R, Comella G, Casaretti R, et al. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer 2001;84(4):470-4.
9. Gallardo-Rincon D, Onate-Ocana LF, Calderillo-Ruiz G. Neoajuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study. Ann Surg Oncol 2000;7(1):45-50.
10. Takahashi S, Kinoshita T, Konishi M, Nakagouri T, Inoue K, Ono M, et al. Phase II study of sequential high-dose methotrexate and fluorouracil combined with doxorubicin as a neoadjuvant chemotherapy for scirrhous gastric cancer. Gastric Cancer 2001; 4(4):192-7.
11. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomized, controlled trial (the MAGIC trial, ISRCTN 9379371). Proc ASCO 2003;22:249